Following the launch of two key products in Europe, leading Australian cannabis company Creso Pharma (ASX: CPH) has listed on the German stock exchange.
Under the code 1X8, Creso is now trading ordinary shares on the Frankfurt Stock Exchange.
The company has also appointed Deutsche Gesellschaft für Wertpapieranalyse GmbH (DGWA) to position Creso in the German speaking media environment and to assist the company in its relations with German retail and institutional investors.
Creso CEO Dr Miri Halperin Wernli says listing on the Frankfurt Stock Exchange was the natural next step for the company's European operations.
"Given our headquarters in Switzerland and our dominant European operations, we were pleased to offer European investors the ability to invest in Creso," says Wernli.
"This was in response to strong investor appetite out of Europe and the Frankfurt exchange. We have already seen success from our products in Europe and anticipate further opportunities for growth and advancement in the region."
The business recently expanded sales of its health products across Europe with cannaQIX now being sold in the Benelux region and in the UK.
The group's international ambitions were also expanded in June after the company appointed John Griese as chief operating officer for the Americas to help establish the company's presence in North America.
More recently, the company completed a successful launch of its cannaQIX 50 product in New Zealand after signing an agreement with a key distributor.
Business News Australia
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support